Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 2/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | CHRND | Q07001 | 5/20 | 0.42 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.42 |
| ▸ | CHRNG | P07510 | 1/20 | 0.42 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23135666 | 0.86 | CTSL (0.44) | FOLH1ACEMMECPA1ACE2 | |
| SCHEMBL16217879 | 0.86 | GRIA1 (0.44) | FOLH1ACEMMECPA1ACE2 | |
| SCHEMBL18879461 | 0.85 | GRIA1 (0.44) | FOLH1ACEMMECPA1ACE2 | |
| SCHEMBL23026392 | 0.85 | CTSL (0.49) | FOLH1ACEMMECPA1ACE2 | |
| SCHEMBL19871860 | 0.84 | OPRD1 (0.39) | FOLH1ACEMMECPA1ACE2 | |
| SCHEMBL20099253 | 0.83 | ACE (0.46) | FOLH1ACEMMECPA1ACE2 | |
| SCHEMBL18973012 | 0.81 | MAPT (0.44) | ACEMMECPA1ACE2 | |
| SCHEMBL22692612 | 0.81 | CTSL (0.40) | FOLH1ACEMMECPA1ACE2 | |
| SCHEMBL27250409 | 0.80 | FOLH1 (0.51) | FOLH1ACEMMECPA1ACE2 | |
| SCHEMBL26894931 | 0.80 | FOLH1 (0.51) | FOLH1ACEMMECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324900-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2022-10-13 | — | — | US | disclosed |
| US-10883104-B2 | Compositions and methods for modulating apolipoprotein (a) expression | IONIS PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10875884-B2 | Compositions and methods for modulating angiopoietin-like 3 expression | ISIS PHARMACEUTICALS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-10570169-B2 | Conjugated antisense compounds and their use | IONIS PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190016748-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20170355727-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | IONIS PHARMACEUTICALS, INC. (US) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10875884-B2 | Compositions and methods for modulating angiopoietin-like 3 expression | TEK, PLIN3, FABP3 | FOLH1 2357/4885ACE 1925/4885MME 1748/4885 |
| US-20220324900-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | TEK, PLIN3, FABP3 | FOLH1 2357/4885ACE 1925/4885MME 1748/4885 |
| US-10570169-B2 | Conjugated antisense compounds and their use | GNE, GALNT1, GALNT6 | FOLH1 422/4885ACE 1967/4885MME 894/4885 |
| US-10883104-B2 | Compositions and methods for modulating apolipoprotein (a) expression | APOB, APOL1, LDLR | FOLH1 2158/4885ACE 804/4885MME 1267/4885 |
| US-20190016748-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | TEK, PLIN3, FABP3 | FOLH1 2357/4885ACE 1925/4885MME 1748/4885 |
| US-20170355727-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | GNE, GALNT1, GALNT6 | FOLH1 422/4885ACE 1967/4885MME 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.